Matinas BioPharma Statistics Share Statistics Matinas BioPharma has 5.09M
shares outstanding. The number of shares has increased by -0.02%
in one year.
Shares Outstanding 5.09M Shares Change (YoY) -0.02% Shares Change (QoQ) -0.02% Owned by Institutions (%) 5.43% Shares Floating 4.01M Failed to Deliver (FTD) Shares 9 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 150.11K, so 2.7% of the outstanding
shares have been sold short.
Short Interest 150.11K Short % of Shares Out 2.7% Short % of Float 2.71% Short Ratio (days to cover) 2.58
Valuation Ratios The PE ratio is -0.1 and the forward
PE ratio is -0.39.
Matinas BioPharma's PEG ratio is
0.02.
PE Ratio -0.1 Forward PE -0.39 PS Ratio 0 Forward PS 0.1 PB Ratio 0.33 P/FCF Ratio -0.16 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Matinas BioPharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.01,
with a Debt / Equity ratio of 0.38.
Current Ratio 3.01 Quick Ratio 3.01 Debt / Equity 0.38 Debt / EBITDA -0.12 Debt / FCF -0.18 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-8.08M Employee Count 3 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -80K Effective Tax Rate 0.33%
Stock Price Statistics The stock price has increased by -35.55% in the
last 52 weeks. The beta is 1.44, so Matinas BioPharma's
price volatility has been higher than the market average.
Beta 1.44 52-Week Price Change -35.55% 50-Day Moving Average 1.63 200-Day Moving Average 0.92 Relative Strength Index (RSI) 58.03 Average Volume (20 Days) 492,220
Income Statement
Revenue n/a Gross Profit -972K Operating Income -20.16M Net Income -24.25M EBITDA -23.36M EBIT -24.33M Earnings Per Share (EPS) -4.98
Full Income Statement Balance Sheet The company has 7.28M in cash and 2.89M in
debt, giving a net cash position of 4.39M.
Cash & Cash Equivalents 7.28M Total Debt 2.89M Net Cash 4.39M Retained Earnings -199.82M Total Assets 11.42M Working Capital 5.48M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -15.88M
and capital expenditures 0, giving a free cash flow of -15.88M.
Operating Cash Flow -15.88M Capital Expenditures n/a Free Cash Flow -15.88M FCF Per Share -3.26
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields MTNB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for MTNB.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 3, 2024. It was a
backward
split with a ratio of 1:50.
Last Split Date Sep 3, 2024 Split Type backward Split Ratio 1:50
Scores Altman Z-Score -26.56 Piotroski F-Score 2
